InTeleLabs®, a telehealth and personalized medicine company, has launched its proprietary online telehealth platform, elicityTM. elicity offers seamless laboratory testing which bridges the gap between consumers, physicians, and clinical laboratories. The elicity platform empowers patients and consumers with convenient online access to at-home, clinically validated and medically actionable lab testing, combined with on-demand physician support and guidance.
elicity’s initial offering includes a range of clinically validated PGx tests available to consumers online. elicityPGx includes specific tests for individuals on medication for pain management, mental health, and cardiovascular health, as well as a comprehensive test, which provide a wealth of genetic and non-genetic information. While elicityPGx tests are purchased directly by consumers, board-certified physicians order the test, review and interpret the results, and provide follow up to help consumers better understand their personal genetic profile.
“Having meaningful physician involvement at the center of what we do is a vital aspect of the elicity experience.” explains Erik Hennings, CEO and Co-founder of InTeleLabs. “elicity expands on InTeleLabs’ existing telehealth partnerships with clinical laboratories, to drive our continued strategy of expanding access to affordable, clinically validated lab testing.”
The physician consultation is an essential component of elicityPGx testing, allowing consumers to ask questions and to understand their results more precisely in relation to any ongoing treatments and medications. The results and consultation may also provide insights and information that consumers can discuss with their personal physician and agree on any potential treatment changes.
Recent advances in pharmacogenetic science have shown that 95% of a person’s response to a drug is determined by genetics. This means that two people can take the same dose of the same drug but respond in very different ways. PGx testing is a type of genetic test that assesses how likely someone is to respond effectively, or whether they may be at risk for having a serious adverse reaction to certain types of medication.
The arrival of cost-effective and accurate PGx testing provides a valuable asset for clinicians to help them more precisely understand how a patient might respond to certain medications. By aligning prescriptions to an individual’s genetics, physicians can improve quality of care, reduce cost, and minimize adverse reactions to prescription medications – a serious issue in the U.S., killing more than 100,000 people each year.
As part of a phased roll-out plan over the next 6 to 12 months, InTeleLabs is looking to expand its portfolio of products through strategic laboratory partnerships, and introduce additional clinically validated tests, informative to people at all stages in their health journey.
